Finch Therapeutics Group, Inc. (FNCHQ): Nasdaq/NYSE listing notice — Nasdaq says Finch is a 'public shell', seeks delisting; company appeals

Finch Therapeutics Group, Inc.

Nasdaq notified Finch on Feb 16, 2024 that it believes the company is a public shell and continued listing is unwarranted.
Finch disagrees and has requested an appeal hearing, which automatically stays any suspension or delisting pending the hearing.
No assurance that the appeal will succeed or that Finch can maintain listing compliance.
Patent litigation trial vs. Rebiotix/Ferring reset from May 20 to Aug 5, 2024.

item 3.01 item 8.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Finch Therapeutics Group, Inc. received a nasdaq delisting notice notice regarding other (rules 5101).

Exchange: nasdaq
Notice: delisting notice
Rules: 5101

Exact text from the filing

February 16, 2024, Finch Therapeutics Group, Inc. (the “Company”) was notified by the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that, based on the Staff’s review of the Company and pursuant to Listing Rule 5101, the Staff believes that the Company no longer has an operating business and is a “public shell” and that the continued listing of its securities is no longer warranted. The Company disagrees with Nasdaq’s determination regarding the Company’s status as a “public shell” and, accordingly, has requested an appeal hearing. The hearing request

View on SEC.gov

Browse all listing & compliance notices →

Finch Therapeutics Group, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-044511

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.